Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis

Abstract

In summary, the improvement in the formation/resorption marker ratio suggests beneficial systemic and local bone effects of infliximab in patients with RA.

Local Interleukin-1-Driven Joint Pathology Is Dependent on Toll-Like Receptor 4 Activation

“…46 Involvement of TLR4 in cartilage destruction makes it an intriguing candidate to target in combination with TNF to provide protection against cartilage destruction, an area where TNF blockers seem to fail. 47 A role for TLR4 in driving cathepsin K expression and the concomitant bone erosion ( Figure 5) is in line with a previous report on promotion of osteoclastogenesis in monocyte cultures by TLR4 stimulation of the co-cultured fibroblast-like synoviocytes. 48 Moreover, this observation is consistent with recent findings in another in vivo model of arthritis in which TLR4 activation was found to be partially responsible for cathepsin K expression in the joint.…”

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy

“…However, in another study of 70 patients with RA treated with infl iximab plus methotrexate, a decrease was observed only in bone resorption markers (urinary excretion of NTX-I and deoxypyridinoline), whereas BAP did not increase (Torikai et al 2006). The same pattern with a rapid decrease of CTX-I levels followed by a return to baseline levels at 1 year was observed in several studies in RA (Lange et al 2005;Vis et al 2005Vis et al , 2006Chopin et al 2007), and also in spondylarthropathy (Briot et al 2005). Only one study explored the changes of CTX-I and ICTP under infl iximab over one year (Chopin et al 2007).…”

“…The same pattern with a rapid decrease of CTX-I levels followed by a return to baseline levels at 1 year was observed in several studies in RA (Lange et al 2005;Vis et al 2005Vis et al , 2006Chopin et al 2007), and also in spondylarthropathy (Briot et al 2005). Only one study explored the changes of CTX-I and ICTP under infl iximab over one year (Chopin et al 2007). ICTP level showed a later decrease compared to CTX-I, suggesting different specifi c resorption processes.…”

Impact of Biological Therapy on Bone in Patients With Rheumatoid Arthritis

“…В исследовании F. Chopin и соавт. [32] изучено соот-ношение между сывороточными маркерами формирова-ния кости и ее деградацией на фоне длительного (54 нед) лечения ИНФ. В качестве маркера формирования ис-пользован N-терминальный пептид проколлагена I типа (PINP), в качестве маркеров деградации -два фрагмента C-терминального телопептида коллагена I типа (CTX-I и ICTP).…”

“…Кроме того, иммунные клетки и их медиаторы оказывают влияние на продукцию и высвобождение склеростина, таким образом «запуская» Wnt-сигнальный путь, активируя функции ОБ [69,70]. На фоне терапии ингибиторами ФНОα наблюдается уве-личение МПК и массы кости [30,32,71]. Отмечено улуч-шение костного ремоделирования после применения ин-гибитора рецептора ИЛ6 [72].…”